Fenofibrate extended-release tablets
Function and Efficacy
It is a clofibrate lipid regulator that can inhibit the synthesis of cholesterol and triglycerides and increase the excretion of sterols. In addition, it can also reduce plasma fibrinogen content and platelet viscosity and reduce thrombus formation.
Ingredients
The main ingredient of this product is fenofibrate. Molecular weight: C20H21ClO4
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| FenofibrateIngredients |
It is a clofibrate lipid regulator that can inhibit the synthesis of cholesterol and triglycerides and increase the excretion of sterols. In addition, it can also reduce plasma fibrinogen content and platelet viscosity and reduce thrombus formation. More |
49562-28-9 | 63 |
Appearance
This product is a hard capsule, and the contents are white pills.
Indication
No data yet
Usage and Dosage
Adults: Oral, 0.25g each time, once a day.
Adverse Reactions
A small number of patients experience gastrointestinal discomfort, belching, or transient increases in serum transaminases and blood urea nitrogen after taking the medicine; occasionally dry mouth, decreased appetite, increased frequency of bowel movements, abdominal distension, rash, headache, dizziness, and fatigue; rarely, myositis, myalgia, and a significant increase in blood creatine phosphokinase.
Precautions
1. Patients with severe renal impairment. 2. Patients with primary biliary cirrhosis, long-term liver impairment, or existing gallbladder disease. 3. Patients who are allergic to this product.
Special Population Medication
Precautions for children: Not clear. Precautions for pregnancy and lactation: Contraindicated. Precautions for the elderly: The dosage of this product should be appropriately reduced for the elderly.
Drug Interactions
It has an enhanced anticoagulant effect. The dosage of oral anticoagulants used at the same time should be reduced by 1/3, and the dosage should be adjusted according to the test results. It should be used with caution when combined with HMG-CoA reductase inhibitors.
Storage
seal.
Packaging Specification
0.25g
Validity Period
24 months
Manufacturer
Yangtze River Pharmaceutical (Group) Co., Ltd.
-
Founded in:
2001-03-27 -
Address:
No. 1, South Yangtze River Road, Taizhou -
Tax NO.:
913212007286987632 -
Registered Funds:
133 million yuan -
Website:
-
Email: